Literature DB >> 17701465

A primer of amyloid nomenclature.

Per Westermark1, Merrill D Benson, Joel N Buxbaum, Alan S Cohen, Blas Frangione, Shu-Ichi Ikeda, Colin L Masters, Giampaolo Merlini, Maria J Saraiva, Jean D Sipe.   

Abstract

The increasing knowledge of the exact biochemical nature of the localized and systemic amyloid disorders has made a logical and easily understood nomenclature absolutely necessary. Such a nomenclature, biochemically based, has been used for several years but the current literature is still mixed up with many clinical and histochemically based designations from the time when amyloid in general was poorly understood. All amyloid types are today preferably named by their major fibril protein. This makes a simple and rational nomenclature for the increasing number of amyloid disorders known in humans and animals.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17701465     DOI: 10.1080/13506120701460923

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


  96 in total

1.  Toxic fibrillar oligomers of amyloid-β have cross-β structure.

Authors:  James C Stroud; Cong Liu; Poh K Teng; David Eisenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-30       Impact factor: 11.205

2.  Phospholipids enhance nucleation but not elongation of apolipoprotein C-II amyloid fibrils.

Authors:  Timothy M Ryan; Chai L Teoh; Michael D W Griffin; Michael F Bailey; Peter Schuck; Geoffrey J Howlett
Journal:  J Mol Biol       Date:  2010-04-28       Impact factor: 5.469

3.  Mass spectrometry and the amyloid problem--how far can we go in the gas phase?

Authors:  Alison E Ashcroft
Journal:  J Am Soc Mass Spectrom       Date:  2010-03-09       Impact factor: 3.109

4.  Characterizing the assembly of the Sup35 yeast prion fragment, GNNQQNY: structural changes accompany a fiber-to-crystal switch.

Authors:  Karen E Marshall; Matthew R Hicks; Thomas L Williams; Søren Vrønning Hoffmann; Alison Rodger; Timothy R Dafforn; Louise C Serpell
Journal:  Biophys J       Date:  2010-01-20       Impact factor: 4.033

Review 5.  Nonhuman primate models of Alzheimer-like cerebral proteopathy.

Authors:  Eric Heuer; Rebecca F Rosen; Amarallys Cintron; Lary C Walker
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 6.  [Amyloidosis of the heart].

Authors:  A V Kristen; C Röcken
Journal:  Pathologe       Date:  2012-05       Impact factor: 1.011

Review 7.  [Amyloid and amyloidoses].

Authors:  C Röcken; M Eriksson
Journal:  Pathologe       Date:  2009-05       Impact factor: 1.011

8.  Confirmation of local amino acid sequence homology between human prolactin and the amyloid-related proteins.

Authors:  S Benvenga; S Cannavò; F Trimarchi; F Guarneri
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

9.  AL-Base: a visual platform analysis tool for the study of amyloidogenic immunoglobulin light chain sequences.

Authors:  Kip Bodi; Tatiana Prokaeva; Brian Spencer; Maurya Eberhard; Lawreen H Connors; David C Seldin
Journal:  Amyloid       Date:  2009-03       Impact factor: 7.141

Review 10.  Systemic amyloidoses.

Authors:  Luis M Blancas-Mejía; Marina Ramirez-Alvarado
Journal:  Annu Rev Biochem       Date:  2013-02-28       Impact factor: 23.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.